Myosteatosis is associated with poor survival after kidney transplantation: a large retrospective cohort validation
Springer Science and Business Media LLC - Trang 1-13 - 2024
Tóm tắt
We aim to establish diagnostic thresholds of sarcopenia and myosteatosis based on CT measurements, and to validate their prognostic value in a large cohort of kidney transplant recipients. Local healthy population with abdominal CT between 2010 and 2022, and patients underwent kidney transplantation between 2015 and 2019 at our center were retrospectively included. The skeletal muscle index and muscle attenuation of abdominal muscles were calculated based on CT image at the middle of the third lumbar vertebra. Primary endpoints included all-cause mortality and death censored allograft survival. Age- and sex-specific thresholds for sarcopenia and myosteatosis were established based on 1598 healthy local population. The final patient cohort consisted of 992 kidney transplant recipients (median age 34 years, interquartile range 28–44 years; 694 males), including 33 (3.3%) with sarcopenia and 95 (9.5%) with myosteatosis. Multivariate analysis revealed myosteatosis (adjusted hazard ratio = 3.08, p = 0.022) was an independent baseline risk factor of mortality after adjusting for age, the history of cancer, and the history of cardiovascular event. Multivariate analysis found preemptive transplantation (adjusted hazard ratio = 0.36, p = 0.037) was an independent protective factor of allograft loss. No difference was found in the prognosis between kidney transplant recipients with and without sarcopenia. Myosteatosis was an independent risk factor of mortality after kidney transplantation, but sarcopenia was not. Neither sarcopenia nor myosteatosis was associated with graft loss.
Tài liệu tham khảo
Cruz-Jentoft AJ, Sayer AA. Sarcopenia. The Lancet. 2019;393:2636–46.
Correa-de-Araujo R, Addison O, Miljkovic I, Goodpaster BH, Bergman BC, Clark RV, et al. Myosteatosis in the Context of Skeletal Muscle Function Deficit: An Interdisciplinary Workshop at the National Institute on Aging. Front Physiol. 2020;11:963.
Morel A, Ouamri Y, Canouï‐Poitrine F, Mulé S, Champy CM, Ingels A, et al. Myosteatosis as an independent risk factor for mortality after kidney allograft transplantation: a retrospective cohort study. J cachexia sarcopenia muscle. 2022;13:386–96.
Amini B, Boyle SP, Boutin RD, Lenchik L. Approaches to Assessment of Muscle Mass and Myosteatosis on Computed Tomography: A Systematic Review. Newman A, editor. The Journals of Gerontology: Series A. 2019;74:1671–8.
Magudia K, Bridge CP, Bay CP, Babic A, Fintelmann FJ, Troschel FM, et al. Population-Scale CT-based Body Composition Analysis of a Large Outpatient Population Using Deep Learning to Derive Age-, Sex-, and Race-specific Reference Curves. Radiology. 2021;298:319–29.
Kong M, Geng N, Zhou Y, Lin N, Song W, Xu M, et al. Defining reference values for low skeletal muscle index at the L3 vertebra level based on computed tomography in healthy adults: A multicentre study. Clinical Nutrition. 2022;41:396–404.
Meier-Kriesche H-U, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4:378–83.
Merion RM, Goodrich NP, Johnson RJ, McDonald SP, Russ GR, Gillespie BW, et al. Kidney transplant graft outcomes in 379 257 recipients on 3 continents. Am J Transplant. 2018;18:1914–23.
Deliège P-G, Braconnier A, Chaix F, Renard Y, Petrache A, Guyot-Colosio C, et al. Skeletal Muscle Index as a Prognostic Marker for Kidney Transplantation in Older Patients. Journal of Renal Nutrition. 2021;31:286–95.
Zhang J, Shi W, Zou M, Zeng Q, Feng Y, Luo Z, et al. Diagnosis, prevalence, and outcomes of sarcopenia in kidney transplantation recipients: A systematic review and meta‐analysis. J cachexia sarcopenia muscle. 2022;jcsm.13130.
Shaver AL, Noyes K, Ochs-Balcom HM, Wilding G, Ray AD, Ma SJ, et al. A Retrospective Cohort Study of Myosteatosis and Quality of Life in Head and Neck Cancer Patients. Cancers (Basel). 2021;13:4283.
Kim Y, Park KS, Yoo JI. Associations between the quality of life in sarcopenia measured with the SarQoL® and nutritional status. Health Qual Life Outcomes. 2021;19:28.
Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA, et al. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation. 2017;101:S7–105.
Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. N Engl J Med. 2012;367:20–9.
Ware JE, Sherbourne CD. The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection. Medical Care. 1992;30:473–83.
Kim H-K, Kim KW, Kim EH, Lee MJ, Bae S-J, Ko Y, et al. Age-related changes in muscle quality and development of diagnostic cutoff points for myosteatosis in lumbar skeletal muscles measured by CT scan. Clinical Nutrition. 2021;40:4022–8.
Fehrman-Ekholm I, Elinder CG, Stenbeck M, Tydén G, Groth CG. Kidney donors live longer. Transplantation. 1997;64:976–8.
Yoon JK, Lee S, Kim KW, Lee JE, Hwang JA, Park T, et al. Reference Values for Skeletal Muscle Mass at the Third Lumbar Vertebral Level Measured by Computed Tomography in a Healthy Korean Population. Endocrinol Metab. 2021;36:672–7.
Lee CH, Kim G-H. Electrolyte and Acid-Base Disturbances Induced by Clacineurin Inhibitors. Electrolyte Blood Press. 2007;5:126.
Kim H-K, Kim C-H. Quality Matters as Much as Quantity of Skeletal Muscle: Clinical Implications of Myosteatosis in Cardiometabolic Health. Endocrinol Metab. 2021;36:1161–74.
Miljkovic I, Vella CA, Allison M. Computed Tomography-Derived Myosteatosis and Metabolic Disorders. Diabetes Metab J. 2021;45:482–91.
Aleixo GFP, Shachar SS, Nyrop KA, Muss HB, Malpica L, Williams GR. Myosteatosis and prognosis in cancer: Systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 2020;145:102839.
Body S, Ligthart MAP, Rahman S, Ward J, May-Miller P, Pucher PH, et al. Sarcopenia and Myosteatosis Predict Adverse Outcomes After Emergency Laparotomy: A Multi-center Observational Cohort Study. Ann Surg. 2022;275:1103–11.
Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CMM, Sawyer MB, Beaumont C, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016;7:126–35.
Dolan RD, Almasaudi AS, Dieu LB, Horgan PG, McSorley ST, McMillan DC. The relationship between computed tomography-derived body composition, systemic inflammatory response, and survival in patients undergoing surgery for colorectal cancer. J Cachexia Sarcopenia Muscle. 2019;10:111–22.
Wilkinson TJ, Miksza J, Yates T, Lightfoot CJ, Baker LA, Watson EL, et al. Association of sarcopenia with mortality and end-stage renal disease in those with chronic kidney disease: a UK Biobank study. J Cachexia Sarcopenia Muscle. 2021;12:586–98.
van Vliet IMY, Post A, Kremer D, Boslooper-Meulenbelt K, van der Veen Y, de Jong MFC, et al. Muscle mass, muscle strength and mortality in kidney transplant recipients: results of the TransplantLines Biobank and Cohort Study. J Cachexia Sarcopenia Muscle. 2022;13:2932–43.
Gaillard F, Ould Rabah M, Garcelon N, Touam M, Neuraz A, Legendre C, et al. Allograft function and muscle mass evolution after kidney transplantation. J cachexia sarcopenia muscle. 2022;jcsm.13066.
Oterdoom LH, van Ree RM, de Vries APJ, Gansevoort RT, Schouten JP, van Son WJ, et al. Urinary creatinine excretion reflecting muscle mass is a predictor of mortality and graft loss in renal transplant recipients. Transplantation. 2008;86:391–8.
West MA, van Dijk DPJ, Gleadowe F, Reeves T, Primrose JN, Abu Hilal M, et al. Myosteatosis is associated with poor physical fitness in patients undergoing hepatopancreatobiliary surgery. J Cachexia Sarcopenia Muscle. 2019;10:860–71.